Dual Antiplatelet Therapy

Active Cancer Increases Both Ischemic and Bleeding Risks in Minor Stroke Patients on DAPT: Lessons from the READAPT Study

By MedXY 01/07/2026

A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in remission or without cancer.

Cardiology news

The 30-Day Ischemic Penalty: Why Early Aspirin Withdrawal in ACS Requires Caution

By MedXY 01/03/2026

A landmark analysis from the NEOMINDSET trial demonstrates that while potent P2Y12 inhibitor monotherapy reduces bleeding, it significantly increases ischemic risk in the first 30 days after PCI for acute coronary syndrome, suggesting that the timing of aspirin withdrawal is critical for patient safety.

Cardiology news

Stopping Aspirin After 1 Month Post‑PCI in Low‑Risk AMI: P2Y12 Monotherapy Is Noninferior and Bleeding‑Sparing

By MedXY 12/06/2025

In low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.

Cardiology Clinical Updates news Specialties

Low-Dose Apixaban vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: Insights from the ADALA Trial

By MedXY 09/20/2025

The ADALA randomized trial compared low-dose apixaban with dual antiplatelet therapy post-LAA occlusion, demonstrating superior safety and reduced device-related thrombosis risk with low-dose anticoagulation at 3 months.